China Pharma Holdings Changes Auditors

TL;DR

China Pharma swapped auditors from Friedman LLP to Citrin Cooperman & Company, LLP.

AI Summary

China Pharma Holdings, Inc. announced on May 7, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, Friedman LLP, and has appointed Citrin Cooperman & Company, LLP as its new principal accountant. This change was approved by the Audit Committee of the Board of Directors.

Why It Matters

A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which could impact investor confidence.

Risk Assessment

Risk Level: medium — Changes in auditors can sometimes precede or coincide with financial reporting issues, warranting closer scrutiny.

Key Players & Entities

• China Pharma Holdings, Inc. (company) — Registrant
• Friedman LLP (company) — Former Certifying Accountant
• Citrin Cooperman & Company, LLP (company) — New Certifying Accountant
• May 7, 2024 (date) — Date of earliest event reported

FAQ

Filing Documents

• ea0205550-8k_chinapharma.htm (8-K) — 27KB
• 0001213900-24-040851.txt ( ) — 199KB
• cphi-20240507.xsd (EX-101.SCH) — 3KB
• cphi-20240507_lab.xml (EX-101.LAB) — 33KB
• cphi-20240507_pre.xml (EX-101.PRE) — 22KB
• ea0205550-8k_chinapharma_htm.xml (XML) — 4KB

01. Changes in

Item 4.01. Changes in Registrant's Certifying Accountant. On May 3, 2024, the Securities and Exchange Commission (the " SEC ") issued a Rule 102(e) Order (the " Order ") against B F Borgers CPA PC (" Borgers" ), denying its privilege of appearing or practicing before the SEC as an accountant. As a result of the Order, Borgers may not participate in or perform the audit or review of financial information included in the SEC filings, issue audit reports included in the SEC filings, provide consents with respect to audit reports, or otherwise appear or practice before the SEC. On May 7, 2024, China Pharma Holdings, Inc. (the " Company "), a corporation incorporated under the laws of the State of Nevada, terminated the engagement with Borgers serving as the Company's independent registered public accounting firm. The termination of the engagement with Borgers was approved by the Company's audit committee. The reports of Borgers on the financial statements of the Company as of and for the fiscal years ended December 31, 2023 and 2022 did not contain any adverse opinion or disclaimer of opinion, nor were they modified or qualified as to uncertainty, audit scope or accounting principles except a going concern qualification. During the Company's two most recent fiscal years and the subsequent interim period through May 7, 2024, there were no disagreements with Borgers on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of Borgers, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its report. During the Company's two most recent fiscal years and the subsequent interim period through May 7, 2024, there were no reportable events of the type described in Item 304(a)(1)(v) of Regulation S-K. Borgers is not currently permitted to appear or practice before the SEC, as a result, we are not required to

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 8, 2024 CHINA PHARMA HOLDINGS, INC. By: /s/ Zhilin Li Name: Zhilin Li Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR